The Journal of Allergy and Clinical Immunology
Volume 122, Issue 2 , Pages 254-260.e7 , August 2008

Asthma and the elite athlete: Summary of the International Olympic Committee's Consensus Conference, Lausanne, Switzerland, January 22-24, 2008

  • Kenneth D. Fitch, MBBS, MD

      Affiliations

    • School of Sports Science, Exercise and Health, Faculty of Life Sciences, University of Western Australia, Crawley, Australia
    • Corresponding Author InformationReprint requests: Kenneth D. Fitch, MBBS, MD, School of Sports Science, Exercise and Health, Faculty of Life Sciences, University of Western Australia, M408 Crawley, Western Australia.
    • ,
  • Malcolm Sue-Chu, MBChB, PhD

      Affiliations

    • Department of Lung Medicine, St Olavs Hospital, University Hospital of Trondheim, Trondheim, Norway
    • Department of Circulation and Imaging, Norwegian University of Science and Technology, Trondheim, Norway
    • ,
  • Sandra D. Anderson, PhD, DSc

      Affiliations

    • Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, Australia
    • ,
  • Louis-Philippe Boulet, MD, FCCP, FRCPC

      Affiliations

    • Institut de Cardiologie et de Pneumologie de l'Université Laval, Hôpital Laval, Laval, Québec, Canada
    • ,
  • Robert J. Hancox, MBChB, MD

      Affiliations

    • Department of Preventive and Social Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
    • Department of Respiratory Medicine, Waikato Hospital, Hamilton, New Zealand
    • ,
  • Donald C. McKenzie, MD, PhD

      Affiliations

    • Division of Sports Medicine and the School of Human Kinetics, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • Vibeke Backer, MD, DMSci

      Affiliations

    • Department of Respiratory Medicine L, Bispebjerg University Hospital, Copenhagen, Denmark
    • ,
  • Kenneth W. Rundell, PhD

      Affiliations

    • Human Physiology Laboratory, Marywood University, Scranton, Pa
    • ,
  • Juan M. Alonso, MD

      Affiliations

    • Medical Department, Royal Spanish Athletics Federation, Madrid, Spain
    • Medical and Anti-Doping Commission, International Association of Athletics Federations, Monaco
    • ,
  • Pascale Kippelen, PhD

      Affiliations

    • School of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom
    • ,
  • Joseph M. Cummiskey, MD

      Affiliations

    • Respiratory Medicine, Blackrock Clinic, Dublin, Ireland
    • ,
  • Alain Garnier, MD

      Affiliations

    • World Anti-Doping Agency, Lausanne, Switzerland
    • ,
  • Arne Ljungqvist, MD, PhD

      Affiliations

    • Medical Commission, International Olympic Committee, Lausanne, Switzerland

Received 7 March 2008 ,Revised 3 July 2008 ,Accepted 3 July 2008.

References 

  1. Anderson SD, Fitch K, Perry CP, Sue-Chu M, Crapo R, McKenzie D, et al. Responses to bronchial challenge submitted for approval to use inhaled beta2 agonists prior to an event at the 2002 Winter Olympics. J Allergy Clin Immunol. 2003;111:44–49
  2. Anderson SD, Sue-Chu M, Perry CP, Gratziou C, Kippelen P, McKenzie DC, et al. Bronchial challenges in athletes applying to inhale a beta2-agonist at the 2004 Summer Olympics. J Allergy Clin Immunol. 2006;117:767–773
  3. Fitch KD. b2-Agonists at the Olympic Games. Clin Rev Allergy Immunol. 2006;31:259–268
  4. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis. 1987;136:225–244
  5. Anderson SD, Daviskas E. The mechanism of exercise-induced asthma is…. J Allergy Clin Immunol. 2000;106:453–459
  6. Turcotte H, Langdeau JB, Thibault G, Boulet LP. Prevalence of respiratory symptoms in an athlete population. Respir Med. 2003;97:955–963
  7. Nystad W, Harris J, Borgen JS. Asthma and wheezing among Norwegian elite athletes. Med Sci Sports Exerc. 2000;32:266–270
  8. Alaranta A, Alaranta H, Palmu P, Alha P, Pietila K, Heliovaara M, et al. Asthma medication in Finnish Olympic athletes: no signs of inhaled beta2-agonist overuse. Med Sci Sports Exerc. 2004;36:919–924
  9. Parsons JP, O'Brien JM, Lucarelli MR, Mastronarde JG. Differences in the evaluation and management of exercise-induced bronchospasm between family physicians and pulmonologists. J Asthma. 2006;43:379–384
  10. Rundell KW, Im J, Mayers LB, Wilber RL, Szmedra L, Schmitz HR. Self-reported symptoms and exercise-induced asthma in the elite athlete. Med Sci Sports Exerc. 2001;33:208–213
  11. Dickinson JW, Whyte GP, McConnell AK, Harries MG. Impact of changes in the IOC-MC asthma criteria: a British perspective. Thorax. 2005;60:629–632
  12. Joos GF, O'Connor B, Anderson SD, Chung F, Cockcroft DW, Dahlén B, et al. ERS Task Force. Indirect airway challenges. Eur Respir J. 2003;21:1050–1068
  13. Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, et al. Guidelines for methacholine and exercise challenge testing - 1999. Am J Respir Crit Care Med. 2000;161:309–329
  14. Anderson SD, Argyros GJ, Magnussen H, Holzer K. Provocation by eucapnic voluntary hyperpnoea to identify exercise induced bronchoconstriction. Br J Sports Med. 2001;35:344–347
  15. Brannan JD, Anderson SD, Perry CP, Freed-Martens R, Lassig AR, Charlton B. The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) saline. Respir Res. 2005;6:144
  16. Koskela H, Hyvärinen L, Brannan JD, Chan H-K, Anderson SD. Sensitivity and validity of three bronchial provocation tests to demonstrate the effect of inhaled corticosteroids in asthma. Chest. 2003;124:1341–1349
  17. Hofstra WB, Neijens HJ, Duiverman EJ, Kouwenberg JM, Mulder PG, Kuethe MC, et al. Dose-response over time to inhaled fluticasone propionate: treatment of exercise- and methacholine-induced bronchoconstriction in children with asthma. Pediatr Pulmonol. 2000;29:415–423
  18. Subbarao P, Duong M, Adelroth E, Otis J, Obminski G, Inman M, et al. Effect of ciclesonide dose and duration of therapy on exercise-induced bronchoconstriction in patients with asthma. J Allergy Clin Immunol. 2006;117:1008–1013
  19. Anderson SD. Single dose agents in the prevention of exercise-induced asthma: a descriptive review. Treat Respir Med. 2004;3:365–379
  20. Rundell K, Spiering BA, Baumann JM, Evans TM. Effects of montelukast on airway narrowing from eucapnic voluntary hyperventilation and cold air exercise. Br J Sports Med. 2005;39:232–236
  21. Pearlman DS, van Adelsberg J, Philip G, Tilles SA, Busse W, Hendeles L, et al. Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast. Ann Allergy Asthma Immunol. 2006;97:98–104
  22. Rundell KW, Wilber RL, Szmedra L, Jenkinson DM, Mayers LB, Im J. Exercise-induced asthma screening of elite athletes: field vs laboratory exercise challenge. Med Sci Sports Exerc. 2000;32:309–316
  23. Mannix ET, Manfredi F, Farber MO. A comparison of two challenge tests for identifying exercise-induced bronchospasm in figure skaters. Chest. 1999;115:649–653
  24. Anderson SD, Schoeffel RE, Follet R, Perry CP, Daviskas E, Kendall M. Sensitivity to heat and water loss at rest and during exercise in asthmatic patients. Eur J Respir Dis. 1982;63:459–471
  25. Phillips YY, Jaeger JJ, Laube BL, Rosenthal RR. Eucapnic voluntary hyperventilation of compressed gas mixture: a simple system for bronchial challenge by respiratory heat loss. Am Rev Respir Dis. 1985;131:31–35
  26. Rundell KW, Anderson SD, Spiering BA, Judelson DA. Field exercise vs laboratory eucapnic voluntary hyperventilation to identify airway hyperresponsiveness in elite cold weather athletes. Chest. 2004;125:909–915
  27. Holzer K, Anderson SD, Douglass J. Exercise in elite summer athletes: challenges for diagnosis. J Allergy Clin Immunol. 2002;110:374–380
  28. Holzer K, Douglass J, Anderson SD. Inhaled mannitol: a screening test to identify potential exercise-induced bronchoconstriction in elite athletes. Med Sci Sports Exerc. 2001;33:S314
  29. Smith CM, Anderson SD. Hyperosmolarity as the stimulus to asthma induced by hyperventilation?. J Allergy Clin Immunol. 1986;77:729–736
  30. Eiser NM, Kerrebijn KF, Quanjer PH. Guidelines for standardization of bronchial challenge with (nonspecific) bronchoconstricting agents. Working Group on Bronchial Hyperreactivity SEPCR. Bull Eur Physiopathol Respir. 1983;19:495–514
  31. Cockcroft DW, Murdock KY, Berscheid BA, Gore BP. Sensitivity and specificity of histamine PC20 determination in a random selection of young college students. J Allergy Clin Immunol. 1992;89:23–30
  32. Yan K, Salome C, Woolcock AJ. Rapid method for measurement of bronchial responsiveness. Thorax. 1983;38:760–765
  33. Pedersen L, Winther S, Backer V, Anderson SD, Larsen KR. Airway responses to eucapnic hyperpnea, exercise and methacholine in elite swimmers. Med Sci Sports Exerc. 2008;In press
  34. Bougault V, Turmel J, Boulet LP. Respiratory symptoms and prevalence of airway hyperresponsiveness (AHR) in elite swimmers. Am J Respir Crit Care Med. 2008;177:A998
  35. Barnes NC, Piper PJ, Costello JF. Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects. Thorax. 1984;39:500–504
  36. O'Byrne PM. Leukotrienes in the pathogenesis of asthma. Chest. 1997;111:27S–34S
  37. Stensrud T, Berntsen S, Carlsen KH. Humidity influences exercise capacity in subjects with exercise-induced bronchoconstriction (EIB). Respir Med. 2006;100:1633–1641
  38. Anderson SD, Kippelen P. Exercise-induced bronchoconstriction: pathogenesis. Curr Allergy Asthma Rep. 2005;5:116–122
  39. Anderson SD, Brusasco V, Haahtela T, Popov T. Criteria for diagnosis of asthma, exercise-induced bronchoconstriction and airway hyperresponsiveness for athlete: lessons from the Olympic Games. Eur Respir Mon. 2005;33:48–66
  40. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA). 2006;Available at: http://www.ginasthma.orgAccessed July 15, 2008
  41. Kuehn BM. Education key to treating airway disease: focus on inhaler users, rescue workers, athletes. JAMA. 2007;298:2601–2608
  42. Millqvist E, Bengtsson U, Lowhagen O. Combining a beta2-agonist with a face mask to prevent exercise-induced bronchoconstriction. Allergy. 2000;55:672–675
  43. Spooner C, Spooner G, Rowe B. Mast-cell stabilising agents to prevent exercise-induced bronchoconstriction. Cochrane Database Syst Rev. 2003;4:CD002307
  44. Helenius I, Lumme A, Ounap J, Obase Y, Rytila P, Sarna S, et al. No effect of montelukast on asthma-like symptoms in elite ice hockey players. Allergy. 2004;59:39–44
  45. Sue-Chu M, Karjalainen E-M, Laitinen A, Larsson L, Laitinen LA, Bjermer L. Placebo-controlled study of inhaled budesonide on indices of airways inflammation in bronchoalveolar lavage fluid and bronchial biopsies in cross country skiers. Respiration. 2000;67:417–425
  46. Boulet L-P, Turcotte H, Langdeau JB, Bernier MC. Lower airway inflammatory responses to high-intensity training in athletes. Clin Invest Med. 2005;28:15–22
  47. Helenius I, Lumme A, Haahtela T. Asthma, airway inflammation and treatment in elite athletes. Sports Med. 2005;35:565–574
  48. Lumme A, Haahtela T, Öunap J, Rytilä P, Obase Y, Helenius M, et al. Airway inflammation, bronchial hyperresponsiveness, and asthma in elite ice hockey players. Eur Respir J. 2003;22:113–117
  49. Belda J, Ricart S, Casan P, Giner J, Bellido-Casado J, Torrejon M, et al. Airway inflammation in the elite athlete and type of sport. Br J Sports Med. 2008;42:244–249
  50. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31:143–178
  51. Simons FE, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics. 1997;99:655–659
  52. Ramage L, Lipworth BJ, Ingram CG, Cree IA, Dhillon DP. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med. 1994;88:363–368
  53. Nelson JA, Strauss L, Skowronshi M, Ciufo R, Novak R, McFadden ER. Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med. 1998;339:141–146
  54. Anderson SD, Caillaud C, Brannan JD. b2-Agonists and exercise-induced asthma. Clin Rev Allergy Immunol. 2006;31:163–180
  55. Hancox RJ, Subbarao P, Kamada D, Watson RM, Hargreave FE, Inman MD. Beta2-agonist tolerance and exercise-induced bronchospasm. Am J Respir Crit Care Med. 2002;165:1068–1070
  56. Storms W, Chervinsky P, Ghannam AF, Bird S, Hustad CM, Edelman JM. A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respir Med. 2004;98:1051–1062
  57. Haney S, Hancox RJ. Recovery from bronchoconstriction and bronchodilator tolerance. Clin Rev Allergy Immunol. 2006;31:181–196
  58. Kalra S, Swystun VA, Bhagat R, Cockcroft DW. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest. 1996;109:953–956
  59. Hancox RJ, Aldridge EE, Cowan JO, Flannery EM, Herbison GP, McLachlan CR, et al. Tolerance to beta-agonists during acute bronchoconstriction. Eur Respir J. 1999;14:283–287
  60. Yates DH, Kharitonov S, Barnes PJ. An inhaled glucocorticoid does not prevent tolerance to the protective effect of a long-acting inhaled beta 2-agonist. Am J Respir Crit Care Med. 1996;154:1603–1607
  61. Haney S, Hancox RJ. Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide: two randomised controlled trials. Respir Res. 2007;8:19
  62. Lipworth BJ, Aziz I. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol. J Allergy Clin Immunol. 1999;103:88–92
  63. Koh MS, Tee A, Lasserson TJ, Irving LB. Inhaled corticosteroids compared to placebo for prevention of exercise induced bronchoconstriction. Cochrane Database Syst Rev. 2007;CD002739
  64. Poppius H, Sovijarvi ARA, Tammilehto L. Lack of protective effect of high-dose ipratropium on bronchoconstriction following exercise with cold air breathing in patients with mild asthma. Eur J Respir Dis. 1986;68:319–325
  65. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet. 1998;351:1225–1232
  66. Janson C, Anto J, Burney P, Chinn S, de Marco R, Heinrich J, et al. The European Community Respiratory Health Survey: what are the main results so far? European Community Respiratory Health Survey II. Eur Respir J. 2001;18:598–611
  67. Chinn S, Burney P, Jarvis D, Luczynska C. Variation in bronchial responsiveness in the European Community Respiratory Health Survey (ECRHS). Eur Respir J. 1997;10:2495–2501
  68. Pearce N, Sunyer J, Cheng S, Chinn S, Bjorksten B, Burr M, et al. Comparison of asthma prevalence in the ISAAC and the ECRHS. ISAAC Steering Committee and the European Community Respiratory Health Survey. International Study of Asthma and Allergies in Childhood. Eur Respir J. 2000;16:420–426
  69. McCreanor J, Cullinan P, Nieuwenhuijsen MJ, Stewart-Evans J, Malliarou E, Jarup L, et al. Respiratory effects of exposure to diesel traffic in persons with asthma. N Engl J Med. 2007;357:2348–2358
  70. Karjalainen E-M, Laitinen A, Sue-Chu M, Altraja A, Bjermer L, Laitinen LA. Evidence of airway inflammation and remodeling in ski athletes with and without bronchial hyperresponsiveness to methacholine. Am J Respir Crit Care Med. 2000;161:2086–2091
  71. Larsson K, Ohlsén P, Malmberg P, Rydström P-O, Ulriksen H. High prevalence of asthma in cross country skiers. BMJ. 1993;307:1326–1329
  72. Wilber RL, Rundell L, Szmedra L, Jenkinson DM, Im J, Drake SD. Incidence of exercise-induced bronchospasm in Olympic Winter Sport athletes. Med Sci Sports Exerc. 2000;32:732–737
  73. Sue-Chu M, Henriksen AH, Bjermer L. Non-invasive evaluation of lower airway inflammation in hyper-responsive elite cross-country skiers and asthmatics. Respir Med. 1999;93:719–725
  74. Rundell K. Pulmonary function decay in women ice hockey players: is there a relationship to ice rink air quality?. Inhal Toxicol. 2004;16:117–123
  75. Rundell KW, Spiering BA, Baumann JM, Evans TM. Bronchoconstriction provoked by exercise in a high-particulate-matter environment is attenuated by montelukast. Inhal Toxicol. 2005;17:99–105
  76. Annesi-Maesano I, Moreau D, Caillaud D, Lavaud F, Le Moullec Y, Taytard A, et al. Residential proximity fine particles related to allergic sensitisation and asthma in primary school children. Respir Med. 2007;101:1721–1729
  77. Kleinman MT, Sioutas C, Froines JR, Fanning E, Hamade A, Mendez L, et al. Inhalation of concentrated ambient particulate matter near a heavily trafficked road stimulates antigen-induced airway responses in mice. Inhal Toxicol. 2007;19(suppl 1):117–126
  78. Zielinski H, Mudway IS, Berube KA, Murphy S, Richards R, Kelly FJ. Modeling the interactions of particulates with epithelial lining fluid antioxidants. Am J Physiol. 1999;277:L719–L726
  79. Werz O, Szellas D, Steinhilber D. Reactive oxygen species released from granulocytes stimulate 5-lipoxygenase activity in a B-lymphocytic cell line. Eur J Biochem. 2000;267:1263–1269
  80. Calderon-Garciduenas L, Vincent R, Mora-Tiscareno A, Franco-Lira M, Henriquez-Roldan C, Barragan-Mejia G, et al. Elevated plasma endothelin-1 and pulmonary arterial pressure in children exposed to air pollution. Environ Health Perspect. 2007;115:1248–1253
  81. Rundell KW, Caviston R. Ultrafine and fine particulate matter inhalation decreases exercise performance in healthy subjects. J Strength Cond Res. 2008;22:2–5
  82. Rundell KW, Slee JB, Caviston R, Hollenbach AM. Decreased lung function after inhalation of ultrafine and fine particulate matter during exercise is related to decreased total nitrate in exhaled breath condensate. Inhal Toxicol. 2008;20:1–9
  83. Langdeau J-B, Turcotte H, Bowie DM, Jobin J, Desgagné P, Boulet L-P. Airway hyperresponsiveness in elite athletes. Am J Respir Crit Care Med. 2000;161:1479–1484
  84. Langdeau JB, Boulet LP. Prevalence and mechanisms of development of asthma and airway hyperresponsiveness in athletes. Sports Med. 2001;31:601–616
  85. Sue-Chu M, Larsson L, Moen T, Rennard SI, Bjermer L. Bronchoscopy and bronchoalveolar lavage findings in cross-country skiers with and without “ski asthma. Eur Respir J. 1999;13:626–632
  86. Tschumperlin DJ, Drazen JM. Chronic effects of mechanical force on airways. Annu Rev Physiol. 2006;68:563–583
  87. Kujala UM, Sarna S, Kaprio J, Koskenvuo M. Asthma and other pulmonary diseases in former elite athletes. Thorax. 1996;51:288–292
  88. Helenius I, Rytilä P, Sarna S, Lumme A, Helenius M, Remes V, et al. Effect of continuing or finishing high-level sports on airway inflammation, bronchial hyperresponsiveness, and asthma: a 5-year prospective follow-up study of 42 highly trained swimmers. J Allergy Clin Immunol. 2002;109:962–968
  89. Larsson K, Carlsen K-H, Bonini S. Anti asthmatic drugs: treatment of athletes and exercise-induced bronchoconstriction. Eur Respir Mon. 2005;33:73–88
  90. Sporer BC, Sheel AW, McKenzie DC. Dose response of inhaled salbutamol on exercise performance and urine concentrations. Med Sci Sports Exerc. 2008;40:149–157
  91. Martineau L, Horan MA, Rothwell NJ, Little RA. Salbutamol, a beta 2-adrenoceptor agonist, increases skeletal muscle strength in young men. Clin Sci (Lond). 1992;83:615–621
  92. Berges R, Segura J, Ventura R, Fitch KD, Morton AR, Farre M, et al. Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment. Clin Chem. 2000;46:1365–1375

 Consensus Conference supported by the International Olympic Committee.

 Disclosure of potential conflict of interest: K. D. Fitch is a member of the International Olympic Committee (IOC) Medical Commission and chair of the IOC Independent Asthma Panel. M. Sue-Chu is on the Advisory Board of Novartis and GlaxoSmithKline, has delivered lectures funded by AstraZeneca, has participated in a clinical trial funded by Novartis, and is a member of the IOC Independent Asthma Panel. S. D. Anderson invented the mannitol test for Pharmaxis Ltd and is a member of the IOC Independent Asthma Panel. L.-P. Boulet has received sponsorship or funding from AstraZeneca, GlaxoSmithKline, Merck Frosst, Schering-Plough, Novartis, Alexion, AsthmaTx, Boehringer-Ingelheim, Ception, Genentech, IVAX, MedImmune, Topigen, and Wyeth. D. C. McKenzie has received research funding from the World Anti-Doping Agency and is a member of the IOC Independent Asthma Panel. V. Backer has received research funding from Pharmaxis Ltd and the Danish Lung Association and is a member of the Advisory Board of MSD, Novartis, ALK-Abelló, AstraZeneca, and GlaxoSmithKline. K. W. Rundell has delivered lectures sponsored by Merck and has received research funding from the World Anti-Doping Agency, Pharmaxis, SkyPharma, and Forest Research. P. Kippelen has received research funding from the British Olympic Association and is a member of the IOC Independent Asthma Panel. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(08)01305-5

doi: 10.1016/j.jaci.2008.07.003

The Journal of Allergy and Clinical Immunology
Volume 122, Issue 2 , Pages 254-260.e7 , August 2008

Article Tools

* Image Usage & Resolution